Jagannadha Sastry
Research Associate - Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Jagannadha Sastry is a Research Associate Professor at the University of Texas MD Anderson Cancer Center in the United States. His research primarily focuses on the role of targeted inhibition of Aurora kinase A and its effects on immune checkpoint inhibition efficacy, particularly in human papillomavirus-driven cancers. He contributes to advancing cancer treatment strategies through his innovative research.
Articles (5)
Background Human papillomavirus (HPV)-driven cancers include head and neck squamous cell carcinoma and cervical cancer and represent approximately 5% of all cancer cases worldwide. Standard-of-care chemotherapy, radiotherapy, and immune checkpoint inhibitors (ICIs) are associated with adverse effects and limited responses in patients with HPV-driven cancers. The integration of targeted therapies with ICIs may improve outcomes. In a previous study, we demonstrated that Aurora kinase A ( AURKA , Aurora A) inhibitors lead to apoptosis of human HPV-positive cancer cells in vitro and in vivo. Here, we explored the potential of Aurora A inhibition to enhance response to ICIs in immune-competent preclinical models of HPV-driven cancers. Methods We assessed the induction of apoptosis, DNA damage, and immunogenic cell death (ICD) in response to treatment with the Aurora A inhibitor alisertib in vitro and antitumor efficacy of alisertib as a monotherapy and in combination with ICIs that inhibit programmed cell death protein-1 (PD-1) or cytotoxic T-lymphocyte associated protein 4 (CTLA-4) in murine HPV-positive immune-competent tumor models. In each treatment group, we determined the tumor growth kinetics and long-term survival and assessed the tumor immune microenvironment using polychromatic flow cytometry. Results Aurora A inhibition induced apoptosis, DNA damage, and ICD in vitro in multiple human and murine HPV-positive cancer cell lines. Importantly, Aurora A inhibition induced selective apoptotic depletion of myeloid-derived suppressor cells (MDSCs). In vivo experiments demonstrated that the combination of alisertib with ICIs, specifically anti-CTLA4, resulted in improved survival outcomes by altering the tumor immune microenvironment. This combination enhanced CD8 T-cell infiltration and decreased the frequencies of MDSCs, whereas neither alisertib nor ICIs (anti-PD-1/anti-CTLA-4) alone showed such effects. Conclusion Our study establishes the potential of Aurora A inhibition to sensitize HPV-positive tumors to ICIs, specifically anti-CTLA-4 treatment. This combination strategy resulted in enhanced antitumor efficacy, driven by systemic and intratumoral increases in CD8 T-cell responses and reduced immunosuppressive cell populations, specifically MDSCs. These findings offer insights into the synergistic effects of Aurora A inhibition and ICIs and argue for further investigation and optimization of this combination approach in HPV-driven cancers.
Year:
2025
Human papillomavirus (HPV) integration disrupts host genomic structure and expression, but whether these alterations promote cancer development remains unclear. Multiple genomic analyses of oropharyngeal cancers identified several host fusion genes, including recurrent FGFR3-TACC3 fusions, expressed from rearranged genomic loci adjacent to HPV integration sites. Evolutionary modeling pointed to integration of virus concatemers into the host genome as a common initiating event in fusion formation. Coexpression of HPV16 E6/E7 and FGFR3–TACC3 , but neither alone, was sufficient for tumor development in both xenograft and syngeneic mouse models and led to unique transcriptional programs implicated in carcinogenesis. FGFR3–TACC3 expression decreased the ubiquitination and degradation of E6 and E7, thereby increasing oncoprotein abundance. We conclude that expression of HPV16 oncoproteins and host–gene fusions generated from HPV integration sites can be sufficient for cancer development. Significance: Fusion genes are frequently cancer drivers, but the molecular mechanisms underlying their formation have remained unclear. In this study, we identified HPV integration as the instigator of genomic rearrangements that lead to the formation of FGFR3–TACC3 and other fusion genes. FGFR3–TACC3 expression decreased the ubiquitination and degradation of HPV E6 and E7, furthering the oncogenesis of HPV.
Year:
2025
Purpose: Effective therapy for recurrent head and neck squamous cell carcinoma (HNSCC) that is refractory to chemotherapy and immunotherapy is a considerable need. Aurora kinase A inhibition leads to apoptosis and immunogenic cell death in preclinical models of human papilloma virus (HPV)–driven cancers. Patients and Methods: Alisertib was administered orally twice daily on days 1–7 and pembrolizumab on day 1 of a 21-day cycle to adults with advanced solid tumors (phase I) or with immunotherapy- and platinum-resistant, HPV-positive HNSCC (phase II). Results: The recommended phase II alisertib dose was 40 mg, which had only the expected toxicity including cytopenia that led to dose reductions in two phase II patients at cycles 13 and 16. We saw no objective responses, but the combination led to prolonged stable disease (SD) in several patients, including two of 10 phase I patients (8 and 27 months). Eight of the 15 HPV-positive patients had SD, of which four (heavily pretreated) had ≥6 months, with median overall and progression-free survival durations of 16.8 and 1.4 months, respectively. In circulating immune cells and plasma, patients with SD had markedly higher levels of HLA de novo resistance–expressing NK cells than did progressive disease patients who demonstrated a more immunosuppressive and inflammatory profile. Pharmacokinetics did not indicate any significant drug-drug interactions between pembrolizumab and alisertib. Conclusions: The combination of alisertib and pembrolizumab was well tolerated and led to prolonged SD in some immunotherapy-resistant patients, supporting our hypothesis that Aurora kinase A inhibition can reverse immunotherapy resistance of retinoblastoma protein–deficient HNSCC.
Year:
2025
Supplementary Figure S7. Flow cytometry analyses of circulating lymphocyte subsets in patients with acquired resistance (AR, n =8) or de novo resistance (DR, n=4) to prior anti-PD1 immunotherapy.
Year:
2025
Supplementary Figure S6. Plasma samples collected at the baseline from the participants of the trial were compared between the PD and SD groups of patients by the Luminex analyses to profile various cytokines and chemokines.
Year:
2025
Collaborators (11)
Qi Wang
The University of Texas MD Anderson Cancer Center
Joe Dan Dunn
The University of Texas MD Anderson Cancer Center
Akagi Keiko
The University of Texas MD Anderson Cancer Center
Kevin Coombes
Professor
Georgia Cancer Center at Augusta University
Hai Tran
Associate Professor
The University of Texas MD Anderson Cancer Center
J. Jack Lee
Professor
The University of Texas MD Anderson Cancer Center
Jing Wang
Professor
The University of Texas MD Anderson Cancer Center
LI SHEN
The University of Texas MD Anderson Cancer Center
Maura L. Gillison
The University of Texas MD Anderson Cancer Center
Alexandre Reuben
Assistant Professor
The University of Texas MD Anderson Cancer Center
Faye M. Johnson
Associate Professor
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.